Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma

被引：0
|
作者：
Veenstra, David L. [1 ]
Guzauskas, Gregory F. [1 ]
Spencer, Scott J. [1 ]
Felizzi, Federico [2 ]
Launonen, Aino [2 ]
Dawson, Keith [3 ]
Masaquel, Anthony [3 ]
机构：
[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Genentech Inc, San Francisco, CA 94080 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
biosimilars; cost-effectiveness; immunochemotherapy; IBCL; indolent B-cell lymphoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-199
引用
收藏
页码：S280 / S280
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma
    Kai Xu
    Hong Wu
    Chongchong Zhou
    Yuwen Bao
    Min Yu
    Lingli Zhang
    Xin Li
    International Journal of Clinical Pharmacy, 2023, 45 : 641 - 649
  • [22] Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma
    Xu, Kai
    Wu, Hong
    Zhou, Chongchong
    Bao, Yuwen
    Yu, Min
    Zhang, Lingli
    Li, Xin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (03) : 641 - 649
  • [23] Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
    Huo, Gengwei
    Song, Ying
    Liu, Wei
    Guo, Hua
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [24] Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma
    Delea, Thomas E.
    Sharma, Arati
    Grossman, Aaron
    Eichten, Caitlin
    Fenton, Keenan
    Josephson, Neil
    Richhariya, Akshara
    Moskowitz, Alison J.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 117 - 130
  • [25] Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China
    Zhang, Mengdie
    Xu, Kai
    Lin, Yingtao
    Zhou, Chongchong
    Bao, Yuwen
    Zhang, Lingli
    Li, Xin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [26] Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis
    Kaveh, Sara
    Ghadimi, Nashmil
    Alvar, Amirhossein Zarei
    Roudini, Kamran
    Daroudi, Rajabali
    HEALTH ECONOMICS REVIEW, 2024, 14 (01):
  • [27] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system
    Lang, Wenwang
    Deng, Lian
    Lu, Meijun
    Ouyang, Ming
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 1027 - 1042
  • [28] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
    Li, Jiahao
    Zhang, Tiantian
    Xu, Yongmei
    Lu, Peiyao
    Zhu, Jiaxin
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (14) : 1067 - 1075
  • [29] Cost-Effectiveness of Zanubrutinib Versus Bendamustine and Rituximab in Patients With Untreated Chronic Lymphocytic Leukemia
    Nie, Jing
    Liu, Lihui
    Wu, Huina
    Yuan, Shan
    Tang, Ke
    Wu, Jiyong
    CLINICAL THERAPEUTICS, 2024, 46 (11) : 877 - 882
  • [30] Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
    Zheng, Zhiwei
    Yang, Liu
    Xu, Siqi
    Zhu, Huide
    Cai, Hongfu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345